Market Overview

UPDATE: Jefferies Upgrades Sequenom to Buy on Reimbursement Coverage Outlook

Related SQNM
Sequenom Labs Reports Expanded Int'l Noninvasive Prenatal Testing Service with VisibiliT Test
UPDATE: Jefferies Resumes Coverage On Sequenom On Revised Revenue/EPS Forecasts

Jefferies raised its rating on Sequenom (NASDAQ: SQNM) from Hold to Buy with a reiterated $7 price target.

Jefferies said, "We are upgrading shares of SQNM to Buy (from Hold) based on results from a proprietary survey we conducted of US commercial payors representing some 44 million lives, which indicated SQNM is experiencing meaningful traction obtaining reimbursement coverage for its T21 LDT test at average rates that we find more than acceptable. Our $7 price target (>90% upside) is unchanged."

Sequenom closed at $3.60 on Friday.

Posted-In: JefferiesAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Most Popular

Related Articles (SQNM)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters